Title : PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

Pub. Date : 2015 Apr 20

PMID : 25559818






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patients treated with a combination of trastuzumab and lapatinib who had wild-type PIK3CA obtained a total pathologic complete response (pCR) rate of 53.1%, which decreased to 28.6% in patients with tumors that carried PIK3CA activating mutations (P = .012). Lapatinib phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha Homo sapiens
2 Patients treated with a combination of trastuzumab and lapatinib who had wild-type PIK3CA obtained a total pathologic complete response (pCR) rate of 53.1%, which decreased to 28.6% in patients with tumors that carried PIK3CA activating mutations (P = .012). Lapatinib phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha Homo sapiens